Sigachi Industries Limited has informed the Exchange regarding 'Board Recommends final dividend'.
SIGACHI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sigachi Industries' board met on May 30, 2025 and approved audited standalone and consolidated results for Q4 and FY25 with an unmodified (unqualified) auditor opinion. Standalone FY25 revenue grew about 28% year-on-year to Rs 407.83 crore, while profit after tax rose roughly 16% to Rs 47.67 crore; consolidated revenue rose about 22% to Rs 488.24 crore and PAT grew about 23% to Rs 70.46 crore. The board recommended a modest final dividend of Re 0.10 per share, subject to shareholder approval. It also approved the acquisition of an additional 1,07,17,672 equity shares in subsidiary Trimax Bio Sciences Pvt Ltd for Rs 37.22 crore via conversion of an existing loan/advance, which will raise Sigachi's stake from 80% to 84.59% — classified as a material related party transaction. New cost, internal, and secretarial auditors were appointed for FY26 onwards.
Strong top-line growth and an unqualified audit opinion are positives, though Q4 standalone profit fell sharply from a year ago and the dividend is token, limiting near-term shareholder yield. The Trimax Bio Sciences stake hike is largely an internal restructuring rather than fresh cash outflow, but consolidates control of a USFDA-approved API subsidiary.